Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research
Disease Models & Mechanisms · 2025
DOI: 10.1242/dmm.052225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2025. Verfasst von Luna De Sutter und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven 3000, Belgium. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Translational Research, Biomedical, Xenograft Model Antitumor Assays, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Onderzoeksraad, KU Leuven, KU Leuven, Universitaire Ziekenhuizen Leuven, KU Leuven.
Abstract (Originalsprache)
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal malignancy of the gastrointestinal tract. Most GISTs harbor mutations in oncogenes, such as KIT, and are treated with tyrosine kinase inhibitors (TKIs), such as imatinib. Most tumors develop secondary mutations, inducing drug resistance against the available TKIs, requiring novel therapies. We established a GIST patient-derived xenograft (PDX) platform of GIST that can be used for preclinical drug testing. Tumor tissue from consenting GIST patients was transplanted subcutaneously to NMRI nu/nu mice. Once tumor growth was observed, the tumor was re-transplanted to a next generation of mice. Tumors were characterized histopathologically and molecularly at every re-transplantation and compared with the original patient tumor. We transplanted 112 tumor samples from 99 GIST patients, resulting in 12 established and well-characterized GIST models with different mutations and TKI sensitivity. Three models harbor secondary KIT mutations. One model is characterized by a primary, imatinib-resistant PDGFRA exon 18 p.D842V mutation. Our established platform of well-characterized GIST PDX models, covering the most relevant driver mutations, serves as an excellent tool for preclinical drug testing and tumor biology studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven 3000, Belgium.
- Department of Surgical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven 3000, Belgium.
- Department of Abdominal Surgery, University Hospitals Leuven, Leuven 3000, Belgium.
- Department of Thoracic Surgery, University Hospitals Leuven, Leuven 3000, Belgium.
- Department of Human Genetics, KU Leuven, University Hospitals Leuven, Leuven 3000, Belgium.
- Department of Pathology, University Hospitals Leuven, Leuven 3000, Belgium.
ORCID-Profile: Luna De Sutter
Förderung
- Onderzoeksraad, KU Leuven
- KU Leuven
- Universitaire Ziekenhuizen Leuven, KU Leuven
Zitieren
APA
De Sutter, L., De Cock, L., Wang, C. C., Gorgels, D., Wyns, K., Verbeeck, K., Vanleeuw, U., Douchy, T., Hompes, D., Jaekers, J., Van Raemdonck, D., Vanden Bempt, I., Debiec-Rychter, M., Sciot, R., Wozniak, A., & Schöffski, P. (2025). Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052225
Vancouver
De Sutter L, De Cock L, Wang CC, Gorgels D, Wyns K, Verbeeck K, et al. Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research. Disease Models & Mechanisms. 2025. doi:10.1242/dmm.052225
BibTeX
@article{DeSutter2025,
author = {De Sutter, Luna and De Cock, Lore and Wang, Chao-Chi and Gorgels, Daniël and Wyns, Karo and Verbeeck, Kimberly and Vanleeuw, Ulla and Douchy, Thomas and Hompes, Daphne and Jaekers, Joris and Van Raemdonck, Dirk and Vanden Bempt, Isabelle and Debiec-Rychter, Maria and Sciot, Raf and Wozniak, Agnieszka and Schöffski, Patrick},
title = {Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research},
journal = {Disease Models & Mechanisms},
year = {2025},
doi = {10.1242/dmm.052225}
}
EUVIMED